43 related articles for article (PubMed ID: 12504662)
21. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
[TBL] [Abstract][Full Text] [Related]
22. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
van Wijk FH; Aapro MS; Bolis G; Chevallier B; van der Burg ME; Poveda A; de Oliveira CF; Tumolo S; Scotto di Palumbo V; Piccart M; Franchi M; Zanaboni F; Lacave AJ; Fontanelli R; Favalli G; Zola P; Guastalla JP; Rosso R; Marth C; Nooij M; Presti M; Scarabelli C; Splinter TA; Ploch E; Beex LV; ten Bokkel Huinink W; Forni M; Melpignano M; Blake P; Kerbrat P; Mendiola C; Cervantes A; Goupil A; Harper PG; Madronal C; Namer M; Scarfone G; Stoot JE; Teodorovic I; Coens C; Vergote I; Vermorken JB;
Ann Oncol; 2003 Mar; 14(3):441-8. PubMed ID: 12598351
[TBL] [Abstract][Full Text] [Related]
24. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
[TBL] [Abstract][Full Text] [Related]
25. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Michener CM; Peterson G; Kulp B; Webster KD; Markman M
J Cancer Res Clin Oncol; 2005 Sep; 131(9):581-4. PubMed ID: 15959825
[TBL] [Abstract][Full Text] [Related]
26. The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis.
van Weelden WJ; Birkendahl PB; Lalisang RI; IntHout J; Kruitwagen RFPM; Romano A; Pijnenborg JMA
BJOG; 2023 Jan; 130(2):143-152. PubMed ID: 36264251
[TBL] [Abstract][Full Text] [Related]
27. Arsenic trioxide in the treatment of platinum-resistant recurrent endometrial cancer: a case report and literature review.
Cai H; Li X; Wang J
J Obstet Gynaecol; 2020 Jan; 40(1):137-138. PubMed ID: 31210078
[No Abstract] [Full Text] [Related]
28. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents.
Moxley KM; McMeekin DS
Oncologist; 2010; 15(10):1026-33. PubMed ID: 20930101
[TBL] [Abstract][Full Text] [Related]
29. The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma.
Ray-Coquard I; Monk BJ; Lorusso D; Mahdi H; Upadhyay V; Graul R; Husain A; Mirza MR; Slomovitz B
Int J Gynecol Cancer; 2023 Dec; 33(12):1943-1949. PubMed ID: 37907262
[TBL] [Abstract][Full Text] [Related]
30. [Chemotherapy of advanced endometrial carcinoma].
Stanojević Z; Todorovska I; Dordević B; Lilić V; Zivanović D
Vojnosanit Pregl; 2007 Aug; 64(8):555-60. PubMed ID: 17874724
[No Abstract] [Full Text] [Related]
31. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
[TBL] [Abstract][Full Text] [Related]
32. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
Waterhouse DM; Reynolds RK; Natale RB
Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]